Randall E. Harris
Springer Netherlands
2007e druk, 2007
9781402056871
Inflammation in the Pathogenesis of Chronic Diseases
The COX-2 Controversy
Specificaties
Gebonden, 324 blz.
|
Engels
Springer Netherlands |
2007e druk, 2007
ISBN13: 9781402056871
Rubricering
Onderdeel van serie
Subcellular Biochemistry
Verwachte levertijd ongeveer 9 werkdagen
Samenvatting
In this book, a worldwide panel of leading experts discuss the role of inflammation in the pathogenesis of major chronic diseases and the current controversy regarding risk versus benefit of selective cyclooxygenase-2 (COX-2) inhibitors. The authors provide exciting and enlightening perspectives on COX-2 and related molecular targets in the future of medicine, including historical perspectives.
Specificaties
ISBN13:9781402056871
Taal:Engels
Bindwijze:gebonden
Aantal pagina's:324
Uitgever:Springer Netherlands
Druk:2007
Serie:Subcellular Biochemistry
Inhoudsopgave
Preface
Contributors
I. Historical Perspectives
CHAPTER 1. Anti-inflammatory Drugs in the 21st Century
K. D. Rainsford, PhD
II. Inflammatory Mechanisms of Pathogenesis
CHAPTER 2. Nitric oxide synthase and cyclooxygenase interactions in cartilage and meniscus: relationships to joint physiology, arthritis, and tissue repair
J. Brice Weinberg, MD, Beverley Fermor, PhD, Farshid Guilak, PhD
CHAPTER 3. obesity, inflammation, and vascular disease: The Role of the Adipose Tissue as an Endocrine Organ
Paolo Calabro’, MD, Edward T. H. Yeh, MD
Chapter 4. COX-2 and THE Inflammogenesis of Cancer
Randall E. Harris, MD, PhD
CHAPTER 5. Role of COX-2 in Inflammatory AND DEGENERATIVE Brain Diseases
Luisa Minghetti, PhD
III. Inflammation and Cardiovascular Disease: the Coxib Controversy
CHAPTER 6. Cardiovascular Effects of the Selective Cyclooxygenase-2 Inhibitors
William B. White, MD
CHAPTER 7. COX-2 inhibitors and Cardiovascular Risk
Daniel J. Salzberg, MD, Matthew R. Weir, MD
CHAPTER 8. A BIOLOGICAL RATIONALE FOR THE CARDIOTOXIC EFFECTS OF ROFECOXIB: COMPARATIVE Analysis with other COX-2 Selective Agents and NSAIDs
R. Preston Mason, PhD, Mary F. Walter, PhD, Charles A. Day, Robert F. Jacob, PhD
IV. COX-2 Blockade in Cancer Prevention and Therapy
CHAPTER 9. Cancer Chemoprevention by COX-2 Blockade: Results of Case Control Studies.
Randall E. Harris, MD, PhD, Joanne Beebe-Donk, Galal A. Alshafie, MD, PhD
CHAPTER 10. Strategies for Colon Cancer Prevention:
Combination of Chemopreventive Agents
Bandaru S. Reddy, DVM, PhD
V. Inflammation and Neurodegenerative Disease
CHAPTER 11. NSAIDs FOR THE Chemoprevention of Alzheimer’s Disease
Christine A. Szekely, Ph.D., Terrence Town, Ph.D, Peter P. Zandi,Ph.D
CHAPTER 12. Inflammation in Parkinson’s disease:
causative or epiphenomenal?
Andreas Hald, PhD, Johan van Beek, PhD, and Julie Lotharius, PhD
VI. Nutrition, Inflammation and Chronic Disease
CHAPTER 13. NUTRITION, INFLAMMATION, AND CARDIOVASCULAR DISEASE
Michel de Logeril, MD
CHAPTER 14. NUTRITION, INFLAMMATION & bRAIN AGING
Frances C. Lau, PhD, Barbara Shukitt-Hale, PhD, James Joseph, PhD
INDEX
Contributors
I. Historical Perspectives
CHAPTER 1. Anti-inflammatory Drugs in the 21st Century
K. D. Rainsford, PhD
II. Inflammatory Mechanisms of Pathogenesis
CHAPTER 2. Nitric oxide synthase and cyclooxygenase interactions in cartilage and meniscus: relationships to joint physiology, arthritis, and tissue repair
J. Brice Weinberg, MD, Beverley Fermor, PhD, Farshid Guilak, PhD
CHAPTER 3. obesity, inflammation, and vascular disease: The Role of the Adipose Tissue as an Endocrine Organ
Paolo Calabro’, MD, Edward T. H. Yeh, MD
Chapter 4. COX-2 and THE Inflammogenesis of Cancer
Randall E. Harris, MD, PhD
CHAPTER 5. Role of COX-2 in Inflammatory AND DEGENERATIVE Brain Diseases
Luisa Minghetti, PhD
III. Inflammation and Cardiovascular Disease: the Coxib Controversy
CHAPTER 6. Cardiovascular Effects of the Selective Cyclooxygenase-2 Inhibitors
William B. White, MD
CHAPTER 7. COX-2 inhibitors and Cardiovascular Risk
Daniel J. Salzberg, MD, Matthew R. Weir, MD
CHAPTER 8. A BIOLOGICAL RATIONALE FOR THE CARDIOTOXIC EFFECTS OF ROFECOXIB: COMPARATIVE Analysis with other COX-2 Selective Agents and NSAIDs
R. Preston Mason, PhD, Mary F. Walter, PhD, Charles A. Day, Robert F. Jacob, PhD
IV. COX-2 Blockade in Cancer Prevention and Therapy
CHAPTER 9. Cancer Chemoprevention by COX-2 Blockade: Results of Case Control Studies.
Randall E. Harris, MD, PhD, Joanne Beebe-Donk, Galal A. Alshafie, MD, PhD
CHAPTER 10. Strategies for Colon Cancer Prevention:
Combination of Chemopreventive Agents
Bandaru S. Reddy, DVM, PhD
V. Inflammation and Neurodegenerative Disease
CHAPTER 11. NSAIDs FOR THE Chemoprevention of Alzheimer’s Disease
Christine A. Szekely, Ph.D., Terrence Town, Ph.D, Peter P. Zandi,Ph.D
CHAPTER 12. Inflammation in Parkinson’s disease:
causative or epiphenomenal?
Andreas Hald, PhD, Johan van Beek, PhD, and Julie Lotharius, PhD
VI. Nutrition, Inflammation and Chronic Disease
CHAPTER 13. NUTRITION, INFLAMMATION, AND CARDIOVASCULAR DISEASE
Michel de Logeril, MD
CHAPTER 14. NUTRITION, INFLAMMATION & bRAIN AGING
Frances C. Lau, PhD, Barbara Shukitt-Hale, PhD, James Joseph, PhD
INDEX